{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:31:12Z","timestamp":1790483472059,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study sought to determine the efficacy and safety profile of cabozantinib in patients with advanced Merkel cell carcinoma (MCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design<\/jats:title>\n                    <jats:p>This prospective, phase II, single-institution trial enrolled patients with platinum-failure, recurrent\/metastatic MCC to receive cabozantinib 60 mg orally daily until disease progression, withdrawal from study, or severe toxicity. The primary endpoint was disease control rate. Secondary endpoints included overall survival (OS), progression-free survival (PFS), and toxicity. Immunohistochemistry for VEGFR-2, MET, and HGF expression and next-generation sequencing of tumor tissue were performed and correlated with outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight patients were accrued from January 24, 2014, to June 8, 2016. The study was closed prematurely because of toxicity and lack of responses. The most frequent adverse events were grades 1 and 2 and included anorexia, fatigue, nausea, hypothyroidism, and dysgeusia. Two patients developed nonhealing, painful ulcers and tumor-skin fistula. One patient had stable disease for 8 months. One patient withdrew from the study after 2 weeks of therapy because of adverse events. Three patients required dose reduction because of toxicity. Median PFS and OS were 2.1 and 11.2 months, respectively. No expression of MET, HGF, or VEGFR-2 was identified in tumor cells by immunohistochemistry of patients\u2019 tissue samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cabozantinib was poorly tolerated and did not demonstrate activity in patients with recurrent\/metastatic, platinum-failure MCC. It is unclear whether preselection of patients with the specific upregulation or genetic alteration in the targets for cabozantinib would have changed the results of this study. (Clinical trial identification number: NCT02036476)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>This phase II study demonstrated poor tolerability and lack of activity of cabozantinib in an unselected group of patients with advanced Merkel cell carcinoma. Although it is unclear whether preselection of patients with the specific upregulation and genetic alterations in targets for cabozantinib would have changed the results of this study, this would have likely led to an extremely rare patient population that would take many years to accrue.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0552","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T13:11:23Z","timestamp":1518613883000},"page":"814-821","source":"Crossref","is-referenced-by-count":35,"title":["Cabozantinib in Patients with Advanced Merkel Cell Carcinoma"],"prefix":"10.1093","volume":"23","author":[{"given":"Guilherme","family":"Rabinowits","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Lezcano","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"McHugh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Reilly","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Thakuria","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Bresler","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette M.","family":"Sholl","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Haddad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"DeCaprio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"2021122511044010100_onco12391-bib-0001","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jaad.2010.02.056","article-title":"Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system","volume":"63","author":"Lemos","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2021122511044010100_onco12391-bib-0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jso.20167","article-title":"Merkel cell carcinoma: Changing incidence trends","volume":"89","author":"Hodgson","year":"2005","journal-title":"J Surg Oncol"},{"key":"2021122511044010100_onco12391-bib-0003","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/cam4.815","article-title":"Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma","volume":"5","author":"Iyer","year":"2016","journal-title":"Cancer Med"},{"key":"2021122511044010100_onco12391-bib-0004","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2000.18.12.2493","article-title":"Chemotherapy in neuroendocrine\/Merkel cell carcinoma of the skin: Case series and review of 204 cases","volume":"18","author":"Tai","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122511044010100_onco12391-bib-0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl 13","key":"2021122511044010100_onco12391-bib-0006","doi-asserted-by":"crossref","first-page":"CT079A","DOI":"10.1158\/1538-7445.AM2017-CT079","article-title":"Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update","volume":"77","author":"Kaufman","year":"2017","journal-title":"Cancer Res"},{"key":"2021122511044010100_onco12391-bib-0007","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122511044010100_onco12391-bib-0008","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":"Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov"},{"key":"2021122511044010100_onco12391-bib-0009","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc1912","article-title":"Invasive growth: A MET-driven genetic programme for cancer and stem cells","volume":"6","author":"Boccaccio","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2021122511044010100_onco12391-bib-0010","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/01.pas.0000155162.33044.4f","article-title":"B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in merkel cell carcinoma and small cell carcinomas","volume":"29","author":"Dong","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"2021122511044010100_onco12391-bib-0011","doi-asserted-by":"crossref","first-page":"e02079","DOI":"10.1128\/mBio.02079-16","article-title":"Merkel cell polyomavirus exhibits dominant control of the tumor genome and transcriptome in virus-associated Merkel cell carcinoma","volume":"8","author":"Starrett","year":"2017","journal-title":"MBio"},{"key":"2021122511044010100_onco12391-bib-0012","first-page":"2587","article-title":"Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma","volume":"27","author":"Kukko","year":"2007","journal-title":"Anticancer Res"},{"key":"2021122511044010100_onco12391-bib-0013","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2217\/fon.13.128","article-title":"Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer","volume":"9","author":"Viola","year":"2013","journal-title":"Future Oncol"},{"key":"2021122511044010100_onco12391-bib-0014","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2021122511044010100_onco12391-bib-0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11912-017-0566-9","article-title":"Cabozantinib: An active novel multikinase inhibitor in renal cell carcinoma","volume":"19","author":"Tannir","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"2021122511044010100_onco12391-bib-0016","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/2159-8290.CD-11-0184","article-title":"High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing","volume":"2","author":"Wagle","year":"2012","journal-title":"Cancer Discov"},{"key":"2021122511044010100_onco12391-bib-0017","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: A targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2021122511044010100_onco12391-bib-0018","doi-asserted-by":"crossref","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"2021122511044010100_onco12391-bib-0019","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1200\/JCO.2009.21.8149","article-title":"Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma","volume":"27","author":"Davids","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122511044010100_onco12391-bib-0020","doi-asserted-by":"crossref","first-page":"9542A","DOI":"10.1200\/JCO.2016.34.15_suppl.9542","article-title":"UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma","volume":"34","author":"Nathan","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511044010100_onco12391-bib-0021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cancergen.2015.11.006","article-title":"Hotspot mutations in polyomavirus positive and negative Merkel cell carcinomas","volume":"209","author":"Veija","year":"2016","journal-title":"Cancer Genet"},{"key":"2021122511044010100_onco12391-bib-0022","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-11-2308","article-title":"Activation of PI3K signaling in Merkel cell carcinoma","volume":"18","author":"Nardi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122511044010100_onco12391-bib-0023","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1158\/0008-5472.CAN-15-0702","article-title":"The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma","volume":"75","author":"Harms","year":"2015","journal-title":"Cancer Res"},{"key":"2021122511044010100_onco12391-bib-0024","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.18632\/oncotarget.6494","article-title":"Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy","volume":"7","author":"Goh","year":"2016","journal-title":"Oncotarget"},{"key":"2021122511044010100_onco12391-bib-0025","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/modpathol.2013.235","article-title":"Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinoma","volume":"27","author":"Cimino","year":"2014","journal-title":"Mod Pathol"},{"key":"2021122511044010100_onco12391-bib-0026","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.2013.54.5954","article-title":"Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122511044010100_onco12391-bib-0027","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","article-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1","volume":"34","author":"Smith","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511044010100_onco12391-bib-0028","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"key":"2021122511044010100_onco12391-bib-0029","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122511044010100_onco12391-bib-0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40262-015-0295-x","article-title":"Population pharmacokinetic model of cabozantinib in patients with medullary thyroid carcinoma and its application to an exposure-response analysis","volume":"55","author":"Miles","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2021122511044010100_onco12391-bib-0031","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12967-014-0294-y","article-title":"Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine","volume":"12","author":"Kwilas","year":"2014","journal-title":"J Transl Med"},{"issue":"suppl 6","key":"2021122511044010100_onco12391-bib-0032","first-page":"774PDA","article-title":"A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors","volume":"27","author":"Apolo","year":"2016","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0552","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0552","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/7\/814\/41915407\/oncolo_23_7_814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/7\/814\/41915407\/oncolo_23_7_814.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T06:34:09Z","timestamp":1660458849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/7\/814\/6439632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,2,14]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0552","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,1]]},"published":{"date-parts":[[2018,2,14]]}}}